Combined, these data suggest a novel role for TRAP1 and oxidative metabolism in cancer progression and candidate targeting of mitochondrial bioenergetics as a strategy to improve cisplatin activity in human ovarian cancer [54]. This evidence concerns the gene TRAP1 and ovarian cancer.